New treatment standards for vulvar cancer 2020
Standard
New treatment standards for vulvar cancer 2020. / Woelber, Linn; Jaeger, Anna; Prieske, Katharina.
In: CURR OPIN OBSTET GYN, Vol. 32, No. 1, 02.2020, p. 9-14.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - New treatment standards for vulvar cancer 2020
AU - Woelber, Linn
AU - Jaeger, Anna
AU - Prieske, Katharina
PY - 2020/2
Y1 - 2020/2
N2 - PURPOSE OF REVIEW: To highlight the recent advances regarding molecular mechanisms and therapeutic strategies in vulvar squamous cell carcinoma (VSCC), a rare but continuously rising disease.RECENT FINDINGS: Clinical research focuses on deescalation especially with regard to surgery. Recurrence patterns have been analyzed to further understand the course of disease showing a persistent risk for local recurrence even several years after the initial diagnosis. The main focuses of recent translational research are the distinct molecular mechanisms behind human papillomavirus (HPV)-positive and -negative VSCC. Next-generation sequencing analyses have highlighted TP53 as central driver mutation in HPV-negative disease. For HPV-independent VSCC, an impaired prognosis with limited disease-free and overall survival has been reported from a large multicenter analysis. Although no targeted agent has been granted approval, the impact of immunotherapy in vulvar cancer has been investigated in basket trials. Therapy response, however, was limited.SUMMARY: Further clinical research should focus on deciphering the molecular mechanisms of tumor development further. Detailed understanding of the molecular landscape will help to find novel therapy targets, fight the disease in advanced stages and thereby improve the quality of life for affected patients.
AB - PURPOSE OF REVIEW: To highlight the recent advances regarding molecular mechanisms and therapeutic strategies in vulvar squamous cell carcinoma (VSCC), a rare but continuously rising disease.RECENT FINDINGS: Clinical research focuses on deescalation especially with regard to surgery. Recurrence patterns have been analyzed to further understand the course of disease showing a persistent risk for local recurrence even several years after the initial diagnosis. The main focuses of recent translational research are the distinct molecular mechanisms behind human papillomavirus (HPV)-positive and -negative VSCC. Next-generation sequencing analyses have highlighted TP53 as central driver mutation in HPV-negative disease. For HPV-independent VSCC, an impaired prognosis with limited disease-free and overall survival has been reported from a large multicenter analysis. Although no targeted agent has been granted approval, the impact of immunotherapy in vulvar cancer has been investigated in basket trials. Therapy response, however, was limited.SUMMARY: Further clinical research should focus on deciphering the molecular mechanisms of tumor development further. Detailed understanding of the molecular landscape will help to find novel therapy targets, fight the disease in advanced stages and thereby improve the quality of life for affected patients.
KW - Carcinoma, Squamous Cell/genetics
KW - Female
KW - High-Throughput Nucleotide Sequencing
KW - Humans
KW - Neoplasm Recurrence, Local/genetics
KW - Papillomaviridae
KW - Vulvar Neoplasms/genetics
U2 - 10.1097/GCO.0000000000000595
DO - 10.1097/GCO.0000000000000595
M3 - SCORING: Review article
C2 - 31876635
VL - 32
SP - 9
EP - 14
JO - CURR OPIN OBSTET GYN
JF - CURR OPIN OBSTET GYN
SN - 1040-872X
IS - 1
ER -